Methods for glyco-engineering plant cells for controlled human O-glycosylation
US9024110B2 · kind B2 · utility
Inventors
Key dates
| Filing date | Mar 23, 2011 |
| Grant date | May 5, 2015 |
| Priority date | — |
| Expiry date | Apr 5, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12P21/005
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
This invention discloses the development of a novel platform for recombinant production of bioactive glycoproteins and cancer specific vaccines in plants. Plants and plant cell cultures have been humanized with respect to human mucin-type protein O-glycosylation. A panel of plant cell factories for production of recombinant glycoproteins with designed human O-glycosylation, including an improved cancer vaccine candidate, has been developed. The platform provides basis for i) production of an essentially unlimited array of O-glycosylated human glycoprotein therapeutics, such as human interferon α2B and podoplanin, and ii) for further engineering of additional cancer specific O-glycans on glycoproteins of therapeutical value. Currently, mammalian cells are required for human O-glycosylation, but plants offer a unique cell platform for engineering O-glycosylation since they do not perform human type O-glycosylation. Introduction of O-glycosylation into plant cells requires i) that wild-type plant cells do not modify the target peptide substrates and ii) that the appropriate enzymes and substrates are introduced into of plant cells such that O-glycosylation in the secretory pathway pro…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.